glp 1 market forecast Obesity GLP-1 GLP-1 Drugs Market Size to

Water-rich foods also contribute significantly to your total fluid intake, such as soups, broths, fruits, vegetables, and smoothies

The large cardiovascular outcomes trials of GLP-1 receptor agonists (LEADER, SUSTAIN-6 and REWIND) have confirmed that this class of medication can lower major adverse cardiovascular events by 12-14% in high-risk individuals, and the link between percent weight loss and cardiovascular risk reduction has led to the expectation that higher percent weight loss will yield greater incremental cardiovascular benefits if this class of drug can be used in combination with amylin receptor agonists

K., Lau, R

3,5

Feng Y, Zhang Z, Tang W, Dai Y